GEORGIA MEDICAID FEE-FOR-SERVICE
HEREDITARY TRANSTHYRETIN AMLOIDOSIS AGENTS PA SUMMARY

<table>
<thead>
<tr>
<th>Preferred</th>
<th>Non-Preferred</th>
</tr>
</thead>
<tbody>
<tr>
<td>N/A</td>
<td>Tegsedi (inotersen)</td>
</tr>
</tbody>
</table>

LENGTH OF AUTHORIZATION: 1 Year

PA CRITERIA:

❖ Approvable for members 18 years of age or older with a diagnosis of polyneuropathy of hereditary transthyretin (hATTR)-mediated amyloidosis who are stage 1 or 2 and have a transthyretin (TTR) mutation confirmed by genotyping

AND

❖ When prescribed by or in consultation with a neurologist or physician who specializes in the treatment of hereditary transthyretin (hATTR)-mediated amyloidosis

AND

❖ The prescriber, member and pharmacy are enrolled in the Tegsedi Risk Evaluation and Mitigation Strategy (REMS) program.

EXCEPTIONS:

❖ Exceptions to these conditions of coverage are considered through the prior authorization process by calling OptumRx at 1-866-525-5827.

PREFERRED DRUG LIST:

❖ For online access to the Preferred Drug List (PDL), please go to http://dch.georgia.gov/preferred-drug-lists.

PA and APPEAL PROCESS:

❖ For online access to the PA process, please go to www.dch.georgia.gov/prior-authorization-process-and-criteria and click on Prior Authorization (PA) Request Process Guide.

QUANTITY LEVEL LIMITATIONS:

❖ For online access to the current Quantity Level Limits (QLL), please go to www.mmis.georgia.gov/portal, highlight Pharmacy and click on Other Documents, then select the most recent quarters QLL List.